Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03325114 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Chlorthalidone in Type 1 Diabetes
A Phase 2 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03325114: Clinical Trial Phase 2 study, sponsored by University of Rochester.
NCT03325114 is a Phase 2 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03325114, a Phase 2 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
Primary Outcome
Change in 24 hour urine calcium excretion
Interventions
- DRUG Chlorthalidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 2 |
Why NCT03325114 stopped before completion
NCT03325114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Chlorthalidone is the first listed.
NCT03325114 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03325114 about?
NCT03325114 is a clinical study titled "Safety and Efficacy of Chlorthalidone in Type 1 Diabetes". This open-label study will determine if chlorthalidone is safe and effective for the use of reducing urinary calcium excretion over 4 weeks in subjects with type 1 diabetes
What is the current status of trial NCT03325114?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-06-28. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03325114?
The interventions under investigation include: Chlorthalidone (DRUG).
Who is sponsoring clinical trial NCT03325114?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03325114's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI